AVE Aventis New Ads

Ventiv Health Announces Sales and Marketing Agreement with Aventis Contract Calls for Over 450 Sales Representatives Focused on Primary Care and Specialist Markets SOMERSET, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. (NASDAQ:VTIV) announced today that it has signed a sales and marketing agreement with Aventis Pharmaceuticals (NYSE:AVE) that incorporates Ventiv's broad range of integrated services. Under the terms of the agreement, Ventiv Health will provide Aventis a specialized sales force of 452 full-time Sales Representatives, 50 Area Managers, a National Business Director, two Project Directors, one Project Manager and one Project Liaison. The scope of the agreement will include sales force recruitment, training, analysis and reporting, as well as full operational support of the Aventis/Ventiv sales force. Ventiv will also provide fulfillment, distribution, and warehousing of samples and literature through its PROMOTECH division. The Aventis/Ventiv team will target both primary care and specialty physicians promoting a variety of products nationwide. "Today's announcement underscores the many solutions that Ventiv offers the pharmaceutical industry," said Eran Broshy, CEO of Ventiv Health. "No matter what their size, all pharmaceutical companies need to flexibly optimize their resources. Ventiv provides a low risk, cost efficient way to partner with an experienced outsourced sales and marketing services provider. This agreement reflects the changing dynamics in the pharmaceutical sales marketplace and Ventiv is on the forefront of this positive change." Commenting on the agreement, Terrell Herring, President and COO, Ventiv Pharma Services(TM) said, "Aventis is an ideal partner for Ventiv Pharma Services since we are able to work collaboratively with the entire Aventis Sales and Marketing team to provide a full range of services. Building a premier sales force for one of the pharmaceutical industry's biggest players is a testament to Ventiv and the quality of our services. We are pleased with this show of confidence and look forward to this working relationship." About Aventis Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of euro 16.79 billion (US $18.99), invested euro 2.86 billion (US $3.24) in research and development and employed approximately 69,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. The company's prescription drugs business is conducted in the U.S. by Aventis Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. For more information, please visit: http://www.aventis-us.com/. About Ventiv Health Ventiv Health, Inc. (NASDAQ:VTIV) is a leading provider of sales, marketing, and compliance solutions to the world's largest pharmaceutical companies as well as to emerging and specialty pharmaceutical and biotech organizations. Ventiv has established its leadership position within the industry based on a long history of building and managing sales teams and providing consultative planning and analytics services across multiple therapeutic areas. The Ventiv delivery model is flexible and client focused, enabling Ventiv to rapidly respond to changing client needs and market conditions across the full spectrum of sales and marketing support, with both integrated and independent programs. These include: Sales and Marketing Teams (Ventiv Sales and Marketing Teams(TM)), Planning and Analytics (Health Products Research(R)), Recruitment (Ventiv Recruitment Services(TM)), Professional Development and Training (Ventiv Professional Development Group(TM)), Marketing Support (PROMOTECH), Data Solutions (Total Data Solutions(TM)), Clinical Support (The Therapeutics Institute(TM)), and Sample Accountability/Patient Assistance Programs (The Franklin Group). Ventiv is a multi-discipline company with a singular focus on providing excellence in customized solutions to meet clients' sales and marketing objectives. Ventiv's approximately 2,600 employees support over forty client organizations. For more information on Ventiv Health, visit http://www.ventiv.com/. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors. DATASOURCE: Ventiv Health, Inc. CONTACT: InvestorsCorporate - John Emery, CFO of Ventiv Health, Inc., +1-732-537-4804, ; or Media - Felicia Vonella of Lazar Partners Ltd., +1-212-867-1762, Web site: http://www.ventiv.com/

Copyright